Loading
Life sciences · Phase 1/2 Trial
ClinicalTrials.gov · October 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1/2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06188520). This is a study registration, not published results. Lead sponsor: AstraZeneca. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 55 participants (ACTUAL). Conditions: ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC). Interventions: DRUG: AZD8421; DRUG: Camizestrant; DRUG: Ribociclib; DRUG: Palbociclib; DRUG: Abemaciclib. Primary outcome measures: Incidence of dose limiting toxicities (DLTs) as defined in the protocol. , From start of treatment until the end of DLT period, assessed up to 28 days.; Incidence of AEs/SAEs , From start of treatment until the end of safety follow-up, approximately 18 months.; Clinically significant changes from baseline in clinical laboratory parameters, vital signs and ECGs. , From start of treatment until the end of safety follow-up, approximately 18 months.; Discontinuation of AZD8421 due to toxicity , From start of treatment until the end of safety follow-up, approximately 18 months.. Brief summary: This study is designed to evaluate AZD8421 alone and in combination with selected targeted anti-cancer drugs in patients with ER+HER2- advanced breast cancer, and patients with metastatic high-grade serious ovarian cancer.